{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:24:20Z","timestamp":1793042660872,"version":"4.5.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T00:00:00Z","timestamp":1536883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s11912-018-0733-7","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T16:43:13Z","timestamp":1536943393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches"],"prefix":"10.1007","volume":"20","author":[{"name":"for the Italian Melanoma Intergroup (IMI)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Palmieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Colombino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Casula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Manca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mandal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cossu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,14]]},"reference":[{"key":"733_CR1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2017.12.024","volume":"92","author":"L Sacchetto","year":"2018","unstructured":"Sacchetto L, Zanetti R, Comber H, Bouchardy C, Brewster DH, Broganelli P, et al. Trends in incidence of thick, thin and in situ melanoma in Europe. Eur J Cancer. 2018;92:108\u201318.","journal-title":"Eur J Cancer"},{"key":"733_CR2","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.tranon.2017.09.007","volume":"10","author":"TM Grzywa","year":"2017","unstructured":"Grzywa TM, Paskal W, W\u0142odarski PK. Intratumor and intertumor heterogeneity in melanoma. Transl Oncol. 2017;10:956\u201375.","journal-title":"Transl Oncol"},{"key":"733_CR3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3389\/fonc.2015.00183","volume":"5","author":"G Palmieri","year":"2015","unstructured":"Palmieri G, Ombra M, Colombino M, Casula M, Sini M, Manca A, et al. Multiple molecular pathways in melanomagenesis: characterization of therapeutic targets. Front Oncol. 2015;5:183.","journal-title":"Front Oncol"},{"key":"733_CR4","first-page":"770","volume":"2016","author":"J Paluncic","year":"1863","unstructured":"Paluncic J, Kovacevic Z, Jansson PJ, Kalinowski D, Merlot AM, Huang ML, et al. Roads to melanoma: key pathways and emerging players in melanoma progression and oncogenic signaling. Biochim Biophys Acta. 1863;2016:770\u201384.","journal-title":"Biochim Biophys Acta"},{"key":"733_CR5","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1200\/EDBK_158808","volume":"35","author":"CM Lovly","year":"2016","unstructured":"Lovly CM, Salama AK, Salgia R. Tumor heterogeneity and therapeutic resistance. Am Soc Clin Oncol Educ Book. 2016;35:e585\u201393.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"733_CR6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12967-017-1341-2","volume":"15","author":"PA Ascierto","year":"2017","unstructured":"Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, et al. Future perspectives in melanoma research \u201cmelanoma bridge\u201d, Napoli, November 30th-3rd December 2016. J Transl Med. 2017;15:236.","journal-title":"J Transl Med"},{"key":"733_CR7","doi-asserted-by":"crossref","unstructured":"Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, et al. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015;107","DOI":"10.1093\/jnci\/djv098"},{"key":"733_CR8","first-page":"1932","volume":"2014","author":"HP Buermans","year":"1842","unstructured":"Buermans HP, den Dunnen JT. Next generation sequencing technology: advances and applications. Biochim Biophys Acta. 1842;2014:1932\u201341.","journal-title":"Biochim Biophys Acta"},{"key":"733_CR9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrg3642","volume":"15","author":"D Sims","year":"2014","unstructured":"Sims D, Sudbery I, Ilott NE, Heger A, Ponting CP. Sequencing depth and coverage: key considerations in genomic analyses. Nat Rev Genet. 2014;15:121\u201332.","journal-title":"Nat Rev Genet"},{"key":"733_CR10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nrg.2016.49","volume":"17","author":"S Goodwin","year":"2016","unstructured":"Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet. 2016;17:333\u201351.","journal-title":"Nat Rev Genet"},{"key":"733_CR11","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","volume":"373","author":"AH Shain","year":"2015","unstructured":"\u2022\u2022 Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med. 2015;373:1926\u201336. Presents the succession of genetic alterations during melanoma progression through NGS-based analysis of primary melanomas and their adjacent precursor lesions, including unequivocally benign lesions, intermediate lesions, and intraepidermal or invasive melanomas.","journal-title":"N Engl J Med"},{"key":"733_CR12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/pcmr.12459","volume":"29","author":"T Zhang","year":"2016","unstructured":"Zhang T, Dutton-Regester K, Brown KM, Hayward NK. The genomic landscape of cutaneous melanoma. Pigment Cell Melanoma Res. 2016;29:266\u201383.","journal-title":"Pigment Cell Melanoma Res"},{"key":"733_CR13","doi-asserted-by":"crossref","first-page":"10001","DOI":"10.1038\/ncomms10001","volume":"6","author":"TS Alioto","year":"2015","unstructured":"\u2022 Alioto TS, Buchhalter I, Derdak S, Hutter B, Eldridge MD, Hovig E, et al. A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Nat Commun. 2015;6:10001. Highlights the methodological strategies required to generate consistent and high-quality whole genome sequencing data for cancer analysis.","journal-title":"Nat Commun"},{"issue":"7","key":"733_CR14","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","unstructured":"\u2022\u2022 Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681\u201396. Represents the largest WES analysis of cutaneous melanoma samples from 333 patients. For the first time, four molecular subtypes are indicated: mutant BRAF, mutant RAS, mutant NF1, and triple- wild-type. The study also provides indications that the lymphocyte infiltrate in tumor microenvironment is not depending on the tumor mutational status.","journal-title":"Cell"},{"key":"733_CR15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"\u2022\u2022 Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545:175\u201380. Represents the largest WGS study on cutaneous, acral and mucosal melanoma samples from 183 patients. It provides detailed data on prevalence of protein-affecting aberrations in candidate driver genes, also summarizing the patterns of signaling pathways recurrently altered in melanomas.","journal-title":"Nature"},{"key":"733_CR16","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/ng.2359","volume":"44","author":"M Krauthammer","year":"2012","unstructured":"Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012;44:1006\u201314.","journal-title":"Nat Genet"},{"key":"733_CR17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell. 2012;150:251\u201363.","journal-title":"Cell"},{"key":"733_CR18","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nature11071","volume":"485","author":"MF Berger","year":"2012","unstructured":"Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012;485:502\u20136.","journal-title":"Nature"},{"key":"733_CR19","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/ng.3427","volume":"47","author":"R Arafeh","year":"2015","unstructured":"Arafeh R, Qutob N, Emmanuel R, Keren-Paz A, Madore J, Elkahloun A, et al. Recurrent inactivating RASA2 mutations in melanoma. Nat Genet. 2015;47:1408\u201310.","journal-title":"Nat Genet"},{"key":"733_CR20","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nbt.3863","volume":"35","author":"R Elkon","year":"2017","unstructured":"Elkon R, Agami R. Characterization of noncoding regulatory DNA in the human genome. Nat Biotechnol. 2017;35:732\u201346.","journal-title":"Nat Biotechnol"},{"key":"733_CR21","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/ng.3335","volume":"47","author":"R Katainen","year":"2015","unstructured":"Katainen R, Dave K, Pitk\u00e4nen E, Palin K, Kivioja T, V\u00e4lim\u00e4ki N, et al. CTCF\/cohesin-binding sites are frequently mutated in cancer. Nat Genet. 2015;47:818\u201321.","journal-title":"Nat Genet"},{"key":"733_CR22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nature15258","volume":"526","author":"T Wiesner","year":"2015","unstructured":"Wiesner T, Lee W, Obenauf AC, Ran L, Murali R, Zhang QF, et al. Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature. 2015;526:453\u20137.","journal-title":"Nature"},{"key":"733_CR23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/pcmr.12571","volume":"30","author":"PA Johansson","year":"2017","unstructured":"Johansson PA, Pritchard AL, Patch AM, Wilmott JS, Pearson JV, Waddell N, et al. Mutation load in melanoma is affected by MC1R genotype. Pigment Cell Melanoma Res. 2017;30:255\u20138.","journal-title":"Pigment Cell Melanoma Res"},{"key":"733_CR24","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/path.5039","volume":"244","author":"S Craig","year":"2018","unstructured":"Craig S, Earnshaw CH, Vir\u00f3s A. Ultraviolet light and melanoma. J Pathol. 2018;244:578\u201385.","journal-title":"J Pathol"},{"key":"733_CR25","doi-asserted-by":"crossref","first-page":"12064","DOI":"10.1038\/ncomms12064","volume":"7","author":"CD Robles-Espinoza","year":"2016","unstructured":"Robles-Espinoza CD, Roberts ND, Chen S, Leacy FP, Alexandrov LB, Pornputtapong N, et al. Germline MC1R status influences somatic mutation burden in melanoma. Nat Commun. 2016;7:12064.","journal-title":"Nat Commun"},{"key":"733_CR26","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16:2598\u2013608.","journal-title":"Mol Cancer Ther"},{"key":"733_CR27","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/pcmr.12279","volume":"27","author":"SJ Furney","year":"2014","unstructured":"Furney SJ, Turajlic S, Stamp G, Thomas JM, Hayes A, Strauss D, et al. The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis. Pigment Cell Melanoma Res. 2014;27:835\u20138.","journal-title":"Pigment Cell Melanoma Res."},{"key":"733_CR28","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1158\/1078-0432.CCR-13-0398","volume":"19","author":"VJ Mar","year":"2013","unstructured":"\u2022 Mar VJ, Wong SQ, Li J, Scolyer RA, McLean C, Papenfuss AT, et al. BRAF\/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin Cancer Res. 2013;19:4589\u201398. Represents a detailed report indicating that the mutation load in melanomas arising in severely sun damaged (SSD) skin is much higher than those from non-SSD skin. Moreover, SSD melanomas present a wider spectrum of mutated genes as compared with non-SSD melanomas, which prevalently carry mutations in BRAF\/NRAS genes.","journal-title":"Clin Cancer Res"},{"key":"733_CR29","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/jid.2014.366","volume":"135","author":"AE Siroy","year":"2015","unstructured":"Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, et al. Beyond BRAF (V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015;135:508\u201315.","journal-title":"J Invest Dermatol"},{"key":"733_CR30","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/bjd.13829","volume":"173","author":"D Shitara","year":"2015","unstructured":"Shitara D, Tell-Mart\u00ed G, Badenas C, Enokihara MM, Al\u00f3s L, Larque AB, et al. Mutational status of naevus-associated melanomas. Br J Dermatol. 2015;173:671\u201380.","journal-title":"Br J Dermatol"},{"key":"733_CR31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3389\/fgene.2015.00215","volume":"6","author":"T Shen","year":"2015","unstructured":"Shen T, Pajaro-Van de Stadt SH, Yeat NC, Lin JC. Clinical applications of next generation sequencing in cancer: from panels, to exomes, to genomes. Front Genet. 2015;6:215.","journal-title":"Front Genet"},{"key":"733_CR32","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.jid.2016.05.103","volume":"136","author":"M Casula","year":"2016","unstructured":"Casula M, Colombino M, Manca A, Carac\u00f2 C, Botti G, Ascierto PA, et al. Low levels of genetic heterogeneity in matched lymph node metastases from patients with melanoma. J Invest Dermatol. 2016;136:1917\u201320.","journal-title":"J Invest Dermatol"},{"key":"733_CR33","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.5858\/arpa.2015-0475-RS","volume":"140","author":"AM Acosta","year":"2016","unstructured":"Acosta AM, Kadkol SS. Mitogen-activated protein kinase signaling pathway in cutaneous melanoma: an updated review. Arch Pathol Lab Med. 2016;140:1290\u20136.","journal-title":"Arch Pathol Lab Med"},{"key":"733_CR34","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cub.2005.01.031","volume":"15","author":"EE Patton","year":"2005","unstructured":"Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol. 2005;15:249\u201354.","journal-title":"Curr Biol"},{"key":"733_CR35","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1038\/onc.2016.526","volume":"36","author":"H Yang","year":"2017","unstructured":"Yang H, Kircher DA, Kim KH, Grossmann AH, VanBrocklin MW, Holmen SL, et al. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma. Oncogene. 2017;36:3842\u201351.","journal-title":"Oncogene"},{"key":"733_CR36","doi-asserted-by":"crossref","first-page":"e111153","DOI":"10.1371\/journal.pone.0111153","volume":"9","author":"L Ding","year":"2014","unstructured":"Ding L, Kim M, Kanchi KL, Dees ND, Lu C, Griffith M, et al. Clonal architectures and driver mutations in metastatic melanomas. PLoS One. 2014;9:e111153.","journal-title":"PLoS One"},{"key":"733_CR37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10555-017-9662-4","volume":"36","author":"FV Filipp","year":"2017","unstructured":"Filipp FV. Precision medicine driven by cancer systems biology. Cancer Metastasis Rev. 2017;36:91\u2013108.","journal-title":"Cancer Metastasis Rev"},{"key":"733_CR38","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1016\/j.ejca.2014.06.009","volume":"50","author":"AP Barbour","year":"2014","unstructured":"Barbour AP, Tang YH, Armour N, Dutton-Regester K, Krause L, Loffler KA, et al. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy. Eur J Cancer. 2014;50:2668\u201376.","journal-title":"Eur J Cancer"},{"key":"733_CR39","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/bjc.2014.287","volume":"111","author":"MS Carlino","year":"2014","unstructured":"Carlino MS, Haydu LE, Kakavand H, Menzies AM, Hamilton AL, Yu B, et al. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. Br J Cancer. 2014;111:292\u20139.","journal-title":"Br J Cancer"},{"key":"733_CR40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3892\/ol.2014.2122","volume":"8","author":"P Rutkowski","year":"2014","unstructured":"Rutkowski P, Gos A, Jurkowska M, Switaj T, Dziewirski W, Zdzienicki M, et al. Molecular alterations in clinical stage III cutaneous melanoma: correlation with clinicopathological features and patient outcome. Oncol Lett. 2014;8:47\u201354.","journal-title":"Oncol Lett"},{"key":"733_CR41","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamaoncol.2015.0493","volume":"1","author":"NE Thomas","year":"2015","unstructured":"Thomas NE, Edmiston SN, Alexander A, Groben PA, Parrish E, Kricker A, et al. Association between NRAS and BRAF mutational status and melanoma-specific survival among patients with higher-risk primary melanoma. JAMA Oncol. 2015;1:359\u201368.","journal-title":"JAMA Oncol"},{"key":"733_CR42","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","volume":"29","author":"GV Long","year":"2011","unstructured":"\u2022 Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29:1239\u201346. Demonstrates the lack of any correlation between the BRAF mutation status and clinicopathologic features in melanoma patients. The presence of BRAF mutations has no impact on disease progression and distant metastasis formation.","journal-title":"J Clin Oncol"},{"key":"733_CR43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40246-017-0109-3","volume":"11","author":"C Philpott","year":"2017","unstructured":"Philpott C, Tovell H, Frayling IM, Cooper DN, Upadhyaya M. The NF1 somatic mutational landscape in sporadic human cancers. Hum Genomics. 2017;11:13.","journal-title":"Hum Genomics"},{"key":"733_CR44","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/1878-0261.12050","volume":"11","author":"H Cirenajwis","year":"2017","unstructured":"Cirenajwis H, Lauss M, Ekedahl H, T\u00f6rngren T, Kvist A, Saal LH, et al. NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics. Mol Oncol. 2017;11:438\u201351.","journal-title":"Mol Oncol"},{"key":"733_CR45","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ng.3361","volume":"47","author":"M Krauthammer","year":"2015","unstructured":"Krauthammer M, Kong Y, Bacchiocchi A, Evans P, Pornputtapong N, Wu C, et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet. 2015;47:996\u20131002.","journal-title":"Nat Genet"},{"key":"733_CR46","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-13-2625","volume":"74","author":"MH Nissan","year":"2014","unstructured":"Nissan MH, Pratilas CA, Jones AM, Ramirez R, Won H, Liu C, et al. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res. 2014;74:2340\u201350.","journal-title":"Cancer Res"},{"key":"733_CR47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/pcmr.12316","volume":"28","author":"M Ranzani","year":"2015","unstructured":"Ranzani M, Alifrangis C, Perna D, Dutton-Regester K, Pritchard A, Wong K, et al. BRAF\/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib. Pigment Cell Melanoma Res. 2015;28:117\u20139.","journal-title":"Pigment Cell Melanoma Res"},{"key":"733_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejcb.2013.12.002","volume":"93","author":"M Kunz","year":"2014","unstructured":"Kunz M. Oncogenes in melanoma: an update. Eur J Cell Biol. 2014;93:1\u201310.","journal-title":"Eur J Cell Biol"},{"key":"733_CR49","doi-asserted-by":"crossref","first-page":"E1296","DOI":"10.1073\/pnas.1513801113","volume":"113","author":"Y Lissanu Deribe","year":"2016","unstructured":"Lissanu Deribe Y, Shi Y, Rai K, Nezi L, Amin SB, Wu CC, et al. Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma. Proc Natl Acad Sci U S A. 2016;113:E1296\u2013305.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"733_CR50","doi-asserted-by":"crossref","first-page":"e1160174","DOI":"10.1080\/23723556.2016.1160174","volume":"3","author":"DY Lissanu","year":"2016","unstructured":"Lissanu DY. Mechanistic insights into the role of truncating PREX2 mutations in melanoma. Mol Cell Oncol. 2016;3:e1160174.","journal-title":"Mol Cell Oncol"},{"key":"733_CR51","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/pcmr.12228","volume":"27","author":"RJ Young","year":"2014","unstructured":"Young RJ, Waldeck K, Martin C, Foo JH, Cameron DP, Kirby L, et al. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4\/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res. 2014;27:590\u2013600.","journal-title":"Pigment Cell Melanoma Res."},{"key":"733_CR52","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pharmthera.2014.12.003","volume":"149","author":"Vipin Yadav","year":"2015","unstructured":"Yadav V, Chen SH, Yue YG, Buchanan S, Beckmann RP, Peng SB. Co-targeting BRAF and cyclin dependent kinases 4\/6 for BRAF mutant cancers. Pharmacol Ther. 2015;149:139\u201349.","journal-title":"Pharmacology & Therapeutics"},{"key":"733_CR53","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/CCO.0000000000000159","volume":"27","author":"B Lee","year":"2015","unstructured":"Lee B, Sandhu S, McArthur G. Cell cycle control as a promising target in melanoma. Curr Opin Oncol. 2015;27:141\u201350.","journal-title":"Curr Opin Oncol"},{"key":"733_CR54","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.celrep.2015.09.057","volume":"13","author":"JH Cho","year":"2015","unstructured":"Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G, et al. AKT1 activation promotes development of melanoma metastases. Cell Rep. 2015;13:898\u2013905.","journal-title":"Cell Rep"},{"key":"733_CR55","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.celrep.2013.12.035","volume":"6","author":"F Janku","year":"2014","unstructured":"Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K\/AKT\/mTOR inhibitors. Cell Rep. 2014;6:377\u201387.","journal-title":"Cell Rep"},{"key":"733_CR56","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1158\/1078-0432.CCR-13-2797","volume":"20","author":"M Atefi","year":"2014","unstructured":"Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res. 2014;20:3446\u201357.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"733_CR57","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1541-7786.MCR-13-0224-T","volume":"12","author":"JM Silva","year":"2014","unstructured":"Silva JM, Bulman C, McMahon M. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation. Mol Cancer Res. 2014;12(3):447\u201363.","journal-title":"Mol Cancer Res"},{"key":"733_CR58","doi-asserted-by":"crossref","first-page":"e1238557","DOI":"10.1080\/2162402X.2016.1238557","volume":"5","author":"MA Deken","year":"2016","unstructured":"Deken MA, Gadiot J, Jordanova ES, Lacroix R, van Gool M, Kroon P, et al. Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. Oncoimmunology. 2016;5:e1238557.","journal-title":"Oncoimmunology"},{"issue":"24","key":"733_CR59","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1038\/s41388-018-0205-4","volume":"37","author":"Q Zuo","year":"2018","unstructured":"Zuo Q, Liu J, Huang L, Qin Y, Hawley T, Seo C, et al. AXL\/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma. Oncogene. 2018;37(24):3275\u201389.","journal-title":"Oncogene"},{"issue":"10","key":"733_CR60","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/cr.2014.95","volume":"24","author":"YS Choi","year":"2014","unstructured":"Choi YS, Fisher DE. UV and melanoma: the TP53 link. Cell Res. 2014;24(10):1157\u20138.","journal-title":"Cell Res"},{"key":"733_CR61","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nature13298","volume":"511","author":"A Viros","year":"2014","unstructured":"Viros A, Sanchez-Laorden B, Pedersen M, Furney SJ, Rae J, Hogan K, et al. Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53. Nature. 2014;511:478\u201382.","journal-title":"Nature"},{"key":"733_CR62","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.febslet.2014.05.008","volume":"588","author":"M Lu","year":"2014","unstructured":"Lu M, Miller P, Lu X. Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapy. FEBS Lett. 2014;588:2616\u201321.","journal-title":"FEBS Lett"},{"key":"733_CR63","doi-asserted-by":"crossref","first-page":"E6744","DOI":"10.1073\/pnas.1520390112","volume":"112","author":"MA Lankenau","year":"2015","unstructured":"Lankenau MA, Patel R, Liyanarachchi S, Maharry SE, Hoag KW, Duggan M, et al. MicroRNA-3151 inactivates TP53 in BRAF-mutated human malignancies. Proc Natl Acad Sci U S A. 2015;112:E6744\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"733_CR64","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/jmcb\/mjw045","volume":"9","author":"A Polo de","year":"2017","unstructured":"de Polo A, Luo Z, Gerarduzzi C, Chen X, Little JB, Yuan ZM. AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex. J Mol Cell Biol. 2017;9:154\u201365.","journal-title":"J Mol Cell Biol"},{"key":"733_CR65","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejca.2015.12.002","volume":"55","author":"M Krayem","year":"2016","unstructured":"Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Sal\u00e8s F, et al. p53 reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E\/K) BRAF melanoma to vemurafenib. Eur J Cancer. 2016;55:98\u2013110.","journal-title":"Eur J Cancer"},{"key":"733_CR66","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/15592294.2014.1003746","volume":"10","author":"D Sarkar","year":"2015","unstructured":"Sarkar D, Leung EY, Baguley BC, Finlay GJ, Askarian-Amiri ME. Epigenetic regulation in human melanoma: past and future. Epigenetics. 2015;10:103\u201321.","journal-title":"Epigenetics"},{"key":"733_CR67","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13148-015-0091-3","volume":"7","author":"JJ Lee","year":"2015","unstructured":"Lee JJ, Sholl LM, Lindeman NI, Granter SR, Laga AC, Shivdasani P, et al. Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-na\u00efve patient melanomas. Clin Epigenetics. 2015;7:59.","journal-title":"Clin Epigenetics"},{"key":"733_CR68","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1541-7786.MCR-13-0422","volume":"12","author":"HL Gold","year":"2014","unstructured":"Gold HL, Wengrod J, de Miera EV, Wang D, Fleming N, Sikkema L, et al. PP6C hotspot mutations in melanoma display sensitivity to Aurora kinase inhibition. Mol Cancer Res. 2014;12:433\u20139.","journal-title":"Mol Cancer Res"},{"key":"733_CR69","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JCO.2013.50.7988","volume":"32","author":"JF Hilton","year":"2014","unstructured":"Hilton JF, Shapiro GI. Aurora kinase inhibition as an anticancer strategy. J Clin Oncol. 2014;32:57\u20139.","journal-title":"J Clin Oncol"},{"key":"733_CR70","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jid.2017.01.021","volume":"137","author":"JA Puig-Butille","year":"2017","unstructured":"Puig-Butille JA, Vinyals A, Ferreres JR, Aguilera P, Cabr\u00e9 E, Tell-Mart\u00ed G, et al. AURKA overexpression is driven by FOXM1 and MAPK\/ERK activation in melanoma cells harboring BRAF or NRAS mutations: impact on melanoma prognosis and therapy. J Investig Dermatol. 2017;137:1297\u2013310.","journal-title":"J Investig Dermatol"},{"key":"733_CR71","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1038\/onc.2014.398","volume":"34","author":"K Hayashi","year":"2015","unstructured":"Hayashi K, Momoi Y, Tanuma N, Kishimoto A, Ogoh H, Kato H, et al. Abrogation of protein phosphatase 6 promotes skin carcinogenesis induced by DMBA. Oncogene. 2015;34:4647\u201355.","journal-title":"Oncogene"},{"key":"733_CR72","doi-asserted-by":"crossref","first-page":"ra27","DOI":"10.1126\/scisignal.aaa0899","volume":"8","author":"J Wengrod","year":"2015","unstructured":"Wengrod J, Wang D, Weiss S, Zhong H, Osman I, Gardner LB. Phosphorylation of eIF2\u03b1 triggered by mTORC1 inhibition and PP6C activation is required for autophagy and is aberrant in PP6C-mutated melanoma. Sci Signal. 2015;8:ra27.","journal-title":"Sci Signal"},{"key":"733_CR73","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ijc.28705","volume":"135","author":"T Cajuso","year":"2014","unstructured":"Cajuso T, H\u00e4nninen UA, Kondelin J, Gylfe AE, Tanskanen T, Katainen R, et al. Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer. Int J Cancer. 2014;135:611\u201323.","journal-title":"Int J Cancer"},{"key":"733_CR74","doi-asserted-by":"crossref","first-page":"45863","DOI":"10.18632\/oncotarget.10244","volume":"7","author":"Y Duan","year":"2016","unstructured":"Duan Y, Tian L, Gao Q, Liang L, Zhang W, Yang Y, et al. Chromatin remodeling gene ARID2 targets cyclin D1 and cyclin E1 to suppress hepatoma cell progression. Oncotarget. 2016;7:45863\u201375.","journal-title":"Oncotarget"},{"issue":"6377","key":"733_CR75","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.aao1710","volume":"359","author":"D Pan","year":"2018","unstructured":"\u2022 Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay RE, Luoma AM, et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018;359(6377):770\u20135. Represents an extensive report on interactions between functional modifications in genes involved in epigenetic regulation and\/or chromatin remodeling and recruitment of cytotoxic T cells in tumor microenvironment.","journal-title":"Science"},{"key":"733_CR76","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1158\/1078-0432.CCR-15-0460","volume":"22","author":"MC Caino","year":"2016","unstructured":"Caino MC, Altieri DC. Molecular pathways: mitochondrial reprogramming in tumor progression and therapy. Clin Cancer Res. 2016;22:540\u20135.","journal-title":"Clin Cancer Res"},{"key":"733_CR77","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10555-017-9657-1","volume":"36","author":"M Kunz","year":"2017","unstructured":"Kunz M, H\u00f6lzel M. The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies. Cancer Metastasis Rev. 2017;36:53\u201375.","journal-title":"Cancer Metastasis Rev"},{"key":"733_CR78","doi-asserted-by":"crossref","first-page":"e111019","DOI":"10.1371\/journal.pone.0111019","volume":"9","author":"K Nozaki","year":"2014","unstructured":"Nozaki K, Kagamu H, Shoji S, Igarashi N, Ohtsubo A, Okajima M, et al. DDX3X induces primary EGFR-TKI resistance based on intratumor heterogeneity in lung cancer cells harboring EGFR-activating mutations. PLoS One. 2014;9:e111019.","journal-title":"PLoS One"},{"key":"733_CR79","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41467-017-00758-3","volume":"8","author":"I Yeh","year":"2017","unstructured":"Yeh I, Lang UE, Durieux E, Tee MK, Jorapur A, Shain AH, et al. Combined activation of MAP kinase pathway and \u03b2-catenin signaling cause deep penetrating nevi. Nat Commun. 2017;8:644.","journal-title":"Nat Commun"},{"key":"733_CR80","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nature24040","volume":"550","author":"H Lu","year":"2017","unstructured":"Lu H, Liu S, Zhang G, Wu B, Zhu Y, Frederick DT, et al. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. 2017;550:133\u20136.","journal-title":"Nature"},{"key":"733_CR81","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2017.03.012","volume":"78","author":"D Massi","year":"2017","unstructured":"Massi D, Romano E, Rulli E, Merelli B, Nassini R, De Logu F, et al. Baseline \u03b2-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients. Eur J Cancer. 2017;78:70\u201381.","journal-title":"Eur J Cancer"},{"issue":"5","key":"733_CR82","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1172\/JCI95351","volume":"128","author":"J\u00e9r\u00e9mie Nsengimana","year":"2018","unstructured":"Nsengimana J, Laye J, Filia A, O'Shea S, Muralidhar S, Po\u017aniak J, et al. \u03b2-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas. J Clin Invest. 2018;2048\u20132063","journal-title":"Journal of Clinical Investigation"},{"key":"733_CR83","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mrrev.2016.11.002","volume":"771","author":"B Heidenreich","year":"2017","unstructured":"Heidenreich B, Kumar R. TERT promoter mutations in telomere biology. Mutat Res. 2017;771:15\u201331.","journal-title":"Mutat Res"},{"key":"733_CR84","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1158\/1078-0432.CCR-17-0980","volume":"23","author":"X Bai","year":"2017","unstructured":"Bai X, Kong Y, Chi Z, Sheng X, Cui C, Wang X, et al. MAPK pathway and TERT promoter gene mutation pattern and its prognostic value in melanoma patients: a retrospective study of 2,793 cases. Clin Cancer Res. 2017;23:6120\u20137.","journal-title":"Clin Cancer Res"},{"key":"733_CR85","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/pcmr.12611","volume":"30","author":"HE Seberg","year":"2017","unstructured":"Seberg HE, Van Otterloo E, Cornell RA. Beyond MITF: Multiple transcription factors directly regulate the cellular phenotype in melanocytes and melanoma. Pigment Cell Melanoma Res. 2017;30:454\u201366.","journal-title":"Pigment Cell Melanoma Res."},{"key":"733_CR86","doi-asserted-by":"crossref","first-page":"e2135","DOI":"10.1038\/cddis.2015.369","volume":"7","author":"G Pathria","year":"2016","unstructured":"Pathria G, Garg B, Borgdorff V, Garg K, Wagner C, Superti-Furga G, et al. Overcoming MITF-conferred drug resistance through dual AURKA\/MAPK targeting in human melanoma cells. Cell Death Dis. 2016;7:e2135.","journal-title":"Cell Death Dis"},{"key":"733_CR87","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12916-017-0851-3","volume":"15","author":"J Wouters","year":"2017","unstructured":"Wouters J, Vizoso M, Martinez-Cardus A, Carmona FJ, Govaere O, Laguna T, et al. Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma. BMC Med. 2017;15:101.","journal-title":"BMC Med"},{"key":"733_CR88","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13148-017-0332-8","volume":"9","author":"G Micevic","year":"2017","unstructured":"Micevic G, Theodosakis N, Bosenberg M. Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. Clin Epigenetics. 2017;9:34.","journal-title":"Clin Epigenetics"},{"key":"733_CR89","doi-asserted-by":"crossref","first-page":"22262","DOI":"10.18632\/oncotarget.14763","volume":"8","author":"L Fattore","year":"2017","unstructured":"Fattore L, Costantini S, Malpicci D, Ruggiero CF, Ascierto PA, Croce CM, et al. MicroRNAs in melanoma development and resistance to target therapy. Oncotarget. 2017;8:22262\u201378.","journal-title":"Oncotarget"},{"key":"733_CR90","doi-asserted-by":"crossref","first-page":"13481","DOI":"10.1073\/pnas.1304227110","volume":"110","author":"JJ Gartner","year":"2013","unstructured":"Gartner JJ, Parker SC, Prickett TD, Dutton-Regester K, Stitzel ML, Lin JC, et al. Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A. 2013;110:13481\u20136.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-018-0733-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-018-0733-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-018-0733-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T22:21:35Z","timestamp":1604960495000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-018-0733-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,14]]},"references-count":90,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["733"],"URL":"https:\/\/doi.org\/10.1007\/s11912-018-0733-7","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,14]]},"assertion":[{"value":"14 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Giuseppe Palmieri, Maria Colombino, Milena Casula, Antonella Manca, Mario Mandal\u00e0, and Antonio Cossu declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"86"}}